As industry momentum continues, oligonucleotide manufacturers are making the leap from benchtop production to commercial scale. The challenges of large-scale oligo manufacturing, however, are exponential in comparison to small scale, lab-based operations.
Read MoreJake Adams
Project Manager
Denver, CO

Jake Adams is a project manager on Denver’s biopharmaceutical team that specializes in the design, construction and operation of biotech, pharmaceutical and advanced technology facilities. Recently, Adams has been involved in the success of large-scale oligonucleotide and peptide synthesis facility design efforts. Adams uses his interpersonal and problem-solving skills to forge working relationships and deliver successful and timely solutions to often urgent and complex issues. His experience across all project phases allows him to identify potential problems before the full impact is realized. Adams provides prompt, effective and creative solutions that bring tangible benefits to clients and their projects when it matters most.
Adams has experience with a wide range of project scales in both greenfield and existing facilities as a process engineer and project manager. In his current role as a project manager, Adams is not only responsible for delivering the project scope but also understanding how various project scenarios change the conditions of success. Adams has delivered projects with a variety of unique conditions, including maximum shutdown duration requirements, accelerated project schedules and sharing spaces with ongoing manufacturing. Adams successfully delivers these projects, in part, because of his familiarity with a multitude of design disciplines, construction approaches and qualification requirements.
Adams is a graduate of Colorado State University with a Bachelor of Science in chemical and biological engineering.
Insights By Jake

Preventing the next pandemic: mRNA vaccines and siRNA oligo therapies
Investing in promising new pharmaceutical platforms like oligonucleotide therapies could reduce the gap between first detection and total eradication in future pandemics.
Read More